Covaxin's phase 1 trial data shows robust response: Bharat Biotech

Indigenous vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech International (BBIL), appeared to inch closer to an approval as its phase 1 clinical trial results showed a ‘’robust’’ immune  response without any serious adverse events, the firm said in a research paper.

Bharat Biotech had recently sought an accelerated approval from the regulator based on phase 1 and phase 2 studies. The company is in the middle of conducting a phase 3 trial with 22,000 subjects. Serum Institute of India, which is partnering Astra Zeneca and Oxford University for Covid vaccine, has also sought an emergency approval. Pfizer-BioNTech too has applied